Eli Lilly and Company broke ground on November 12 on a $3.5 billion manufacturing facility in Fogelsville, in Pennsylvania’s Lehigh Valley. The site will manufacture injectable medicines and devices, including retatrutide, the company’s investigational once-weekly triple hormone receptor agonist for obesity and related conditions, and it is expected to be operational by 2031.
The plant is one piece of a much larger programme. It is the tenth new United States manufacturing site Lilly has announced since 2020, one of four dedicated to injectable medicines and devices alongside Research Triangle Park and Concord in North Carolina and Kenosha in Wisconsin, and part of what the company calls a $50 billion push to expand medicine production in the United States. The groundbreaking followed a similar ceremony in Houston weeks earlier for an oral medicines site.
Lilly expects the facility to create 850 permanent jobs, including engineers, scientists, operations staff and lab technicians, plus about 2,000 construction jobs during the build. The company is already hiring for the site and is targeting LEED Gold certification. Pennsylvania’s governor attended the ceremony; local reporting put the permitting timeline at about two months, with the air quality plan approved in 39 business days, a speed the state presented as part of its pitch for the investment.
The capital is being committed ahead of the product. Retatrutide remains in Phase 3 trials across obesity, type 2 diabetes, cardiovascular outcomes and other indications, and Lilly’s own release states plainly that it cannot be legally sold or marketed for human use. Building a $3.5 billion plant around an unapproved molecule is a statement about how confident the company is in its trial data, and about how long injectable capacity takes to create: a site starting construction now only produces at scale in 2031.